Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

Oncogenic Addiction to ERBB2 Signaling Predicts Response to Trastuzumab in Urothelial Cancer.

Karass M, Bareja R, Shelkey E, Vlachostergios PJ, Robinson BD, Khani F, Mosquera JM, Scherr DS, Sboner A, Tagawa ST, Molina AM, Elemento O, Nanus DM, Faltas BM.

J Natl Compr Canc Netw. 2019 Mar 1;17(3):194-200. doi: 10.6004/jnccn.2018.7264.

PMID:
30865916
2.

Rationale for co-targeting CDK4/6 and FGFR pathways in urothelial carcinoma.

Shohdy KS, Vlachostergios PJ, Abdel-Malek RR, Faltas BM.

Expert Opin Ther Targets. 2018 Dec 17:1-4. doi: 10.1080/14728222.2019.1559828. [Epub ahead of print] No abstract available.

PMID:
30558440
3.

The molecular limitations of biomarker research in bladder cancer.

Vlachostergios PJ, Faltas BM.

World J Urol. 2018 Aug 31. doi: 10.1007/s00345-018-2462-9. [Epub ahead of print]

PMID:
30171455
4.

Antibody-Drug Conjugates in Bladder Cancer.

Vlachostergios PJ, Jakubowski CD, Niaz MJ, Lee A, Thomas C, Hackett AL, Patel P, Rashid N, Tagawa ST.

Bladder Cancer. 2018 Jul 30;4(3):247-259. doi: 10.3233/BLC-180169. Review.

5.

Neuroendocrine Differentiation in Prostate Cancer: Emerging Biology, Models, and Therapies.

Puca L, Vlachostergios PJ, Beltran H.

Cold Spring Harb Perspect Med. 2019 Feb 1;9(2). pii: a030593. doi: 10.1101/cshperspect.a030593. Review.

PMID:
29844220
6.

Treatment resistance in urothelial carcinoma: an evolutionary perspective.

Vlachostergios PJ, Faltas BM.

Nat Rev Clin Oncol. 2018 Aug;15(8):495-509. doi: 10.1038/s41571-018-0026-y. Review.

PMID:
29720713
7.

A critical review on ramucirumab in the treatment of advanced urothelial cancer.

Vlachostergios PJ, Lee A, Thomas C, Walsh R, Tagawa ST.

Future Oncol. 2018 May;14(11):1049-1061. doi: 10.2217/fon-2017-0473. Epub 2017 Dec 12. Review.

PMID:
29231057
8.

Trimodality therapy in variant urothelial carcinoma: choose wisely.

Vlachostergios PJ, Jakubowski C, Tagawa ST.

Transl Androl Urol. 2017 Apr;6(2):322-325. doi: 10.21037/tau.2017.03.59. No abstract available.

9.

Emerging Variants of Castration-Resistant Prostate Cancer.

Vlachostergios PJ, Puca L, Beltran H.

Curr Oncol Rep. 2017 May;19(5):32. doi: 10.1007/s11912-017-0593-6. Review.

10.

Antibody therapeutics for treating prostate cancer: where are we now and what comes next?

Vlachostergios PJ, Galletti G, Palmer J, Lam L, Karir BS, Tagawa ST.

Expert Opin Biol Ther. 2017 Feb;17(2):135-149. doi: 10.1080/14712598.2017.1258398. Epub 2016 Nov 20. Review.

PMID:
27817214
11.

Dual light chain extramedullary myeloma presenting with mediastinal lymphadenopathy and lytic bone lesions.

Vlachostergios PJ, Oikonomou KG, Hussain A, Abbi R, Balmiki RL.

Hematol Oncol Stem Cell Ther. 2016 Dec;9(4):162-164. doi: 10.1016/j.hemonc.2016.02.001. Epub 2016 Mar 17. No abstract available.

12.

Designing a broad-spectrum integrative approach for cancer prevention and treatment.

Block KI, Gyllenhaal C, Lowe L, Amedei A, Amin ARMR, Amin A, Aquilano K, Arbiser J, Arreola A, Arzumanyan A, Ashraf SS, Azmi AS, Benencia F, Bhakta D, Bilsland A, Bishayee A, Blain SW, Block PB, Boosani CS, Carey TE, Carnero A, Carotenuto M, Casey SC, Chakrabarti M, Chaturvedi R, Chen GZ, Chen H, Chen S, Chen YC, Choi BK, Ciriolo MR, Coley HM, Collins AR, Connell M, Crawford S, Curran CS, Dabrosin C, Damia G, Dasgupta S, DeBerardinis RJ, Decker WK, Dhawan P, Diehl AME, Dong JT, Dou QP, Drew JE, Elkord E, El-Rayes B, Feitelson MA, Felsher DW, Ferguson LR, Fimognari C, Firestone GL, Frezza C, Fujii H, Fuster MM, Generali D, Georgakilas AG, Gieseler F, Gilbertson M, Green MF, Grue B, Guha G, Halicka D, Helferich WG, Heneberg P, Hentosh P, Hirschey MD, Hofseth LJ, Holcombe RF, Honoki K, Hsu HY, Huang GS, Jensen LD, Jiang WG, Jones LW, Karpowicz PA, Keith WN, Kerkar SP, Khan GN, Khatami M, Ko YH, Kucuk O, Kulathinal RJ, Kumar NB, Kwon BS, Le A, Lea MA, Lee HY, Lichtor T, Lin LT, Locasale JW, Lokeshwar BL, Longo VD, Lyssiotis CA, MacKenzie KL, Malhotra M, Marino M, Martinez-Chantar ML, Matheu A, Maxwell C, McDonnell E, Meeker AK, Mehrmohamadi M, Mehta K, Michelotti GA, Mohammad RM, Mohammed SI, Morre DJ, Muralidhar V, Muqbil I, Murphy MP, Nagaraju GP, Nahta R, Niccolai E, Nowsheen S, Panis C, Pantano F, Parslow VR, Pawelec G, Pedersen PL, Poore B, Poudyal D, Prakash S, Prince M, Raffaghello L, Rathmell JC, Rathmell WK, Ray SK, Reichrath J, Rezazadeh S, Ribatti D, Ricciardiello L, Robey RB, Rodier F, Rupasinghe HPV, Russo GL, Ryan EP, Samadi AK, Sanchez-Garcia I, Sanders AJ, Santini D, Sarkar M, Sasada T, Saxena NK, Shackelford RE, Shantha Kumara HMC, Sharma D, Shin DM, Sidransky D, Siegelin MD, Signori E, Singh N, Sivanand S, Sliva D, Smythe C, Spagnuolo C, Stafforini DM, Stagg J, Subbarayan PR, Sundin T, Talib WH, Thompson SK, Tran PT, Ungefroren H, Vander Heiden MG, Venkateswaran V, Vinay DS, Vlachostergios PJ, Wang Z, Wellen KE, Whelan RL, Yang ES, Yang H, Yang X, Yaswen P, Yedjou C, Yin X, Zhu J, Zollo M.

Semin Cancer Biol. 2015 Dec;35 Suppl:S276-S304. doi: 10.1016/j.semcancer.2015.09.007. Review.

13.

Fecal DNA testing for colorectal cancer screening: Molecular targets and perspectives.

Dhaliwal A, Vlachostergios PJ, Oikonomou KG, Moshenyat Y.

World J Gastrointest Oncol. 2015 Oct 15;7(10):178-83. doi: 10.4251/wjgo.v7.i10.178. Review.

14.

Elevated lactic acid is a negative prognostic factor in metastatic lung cancer.

Vlachostergios PJ, Oikonomou KG, Gibilaro E, Apergis G.

Cancer Biomark. 2015;15(6):725-34. doi: 10.3233/CBM-150514.

PMID:
26406401
15.

Feasibility of energy medicine in a community teaching hospital: an exploratory case series.

Dufresne F, Simmons B, Vlachostergios PJ, Fleischner Z, Joudeh R, Blakeway J, Julliard K.

J Altern Complement Med. 2015 Jun;21(6):339-49. doi: 10.1089/acm.2014.0157. Epub 2015 May 26.

16.

Efficacy of low dose temozolomide in combination with bortezomib in U87 glioma cells: a flow cytometric analysis.

Vlachostergios PJ, Papandreou CN.

Arch Med Sci. 2015 Apr 25;11(2):307-10. doi: 10.5114/aoms.2013.36919. Epub 2013 Aug 12.

17.

Composite angioimmunoblastic T-cell and diffuse large B-cell lymphoma.

Alperovich A, Vlachostergios PJ, Binder A, Oliff AH, Balmiki RL, Dufresne F.

Hematol Oncol Stem Cell Ther. 2015 Sep;8(3):136-7. doi: 10.1016/j.hemonc.2015.04.006. Epub 2015 Apr 28. No abstract available.

18.

Sustained proliferation in cancer: Mechanisms and novel therapeutic targets.

Feitelson MA, Arzumanyan A, Kulathinal RJ, Blain SW, Holcombe RF, Mahajna J, Marino M, Martinez-Chantar ML, Nawroth R, Sanchez-Garcia I, Sharma D, Saxena NK, Singh N, Vlachostergios PJ, Guo S, Honoki K, Fujii H, Georgakilas AG, Bilsland A, Amedei A, Niccolai E, Amin A, Ashraf SS, Boosani CS, Guha G, Ciriolo MR, Aquilano K, Chen S, Mohammed SI, Azmi AS, Bhakta D, Halicka D, Keith WN, Nowsheen S.

Semin Cancer Biol. 2015 Dec;35 Suppl:S25-S54. doi: 10.1016/j.semcancer.2015.02.006. Epub 2015 Apr 17. Review.

19.

Acute renal infarction associated with homozygous methylenetetrahydrofolate reductase mutation C677T and IgA beta-2-glycoprotein antibodies.

Vlachostergios PJ, Dufresne F.

Blood Coagul Fibrinolysis. 2015 Jul;26(5):583-5. doi: 10.1097/MBC.0000000000000295.

PMID:
25828971
20.

Saddle pulmonary embolism as the initial manifestation of pancreatic cancer.

Vlachostergios PJ, Oikonomou KG, Cheema MA, Apergis G.

Intern Med. 2015;54(6):687-8. doi: 10.2169/internalmedicine.54.3651. Epub 2015 Jan 15. No abstract available.

21.

Targeting neuroendocrine prostate cancer: molecular and clinical perspectives.

Vlachostergios PJ, Papandreou CN.

Front Oncol. 2015 Feb 2;5:6. doi: 10.3389/fonc.2015.00006. eCollection 2015. Review.

22.

Angiomyolipomas, renal cell carcinomas and pulmonary lymphangioleiomyomatosis.

Vlachostergios PJ, Rad BS, Karimi K, Apergis G.

J Clin Diagn Res. 2014 Oct;8(10):MJ01. doi: 10.7860/JCDR/2014/9733.5021. Epub 2014 Oct 20. No abstract available.

23.

Common hepatic duct stricture: are lithiasis and negative brush cytology enough to rule out Klatskin tumor?

Vlachostergios PJ, Apergis G.

J Gastrointest Oncol. 2014 Aug;5(4):E73-4. doi: 10.3978/j.issn.2078-6891.2014.041.

24.

Bone metastases and hypercalcaemia from cutaneous squamous cell carcinoma.

Vlachostergios PJ, Balmiki RL.

BMJ Case Rep. 2014 Jun 9;2014. pii: bcr2014204947. doi: 10.1136/bcr-2014-204947. No abstract available.

25.

Efficacy of zibotentan in colorectal cancer--letter.

Vlachostergios PJ.

Mol Cancer Ther. 2014 Jun;13(6):1673. doi: 10.1158/1535-7163.MCT-13-0819. Epub 2014 May 16. No abstract available.

26.

The shaping of invasive glioma phenotype by the ubiquitin-proteasome system.

Vlachostergios PJ, Voutsadakis IA, Papandreou CN.

Cell Commun Adhes. 2013 Oct;20(5):87-92. doi: 10.3109/15419061.2013.833192. Epub 2013 Sep 5. Review.

PMID:
24004256
27.

Mechanisms of proteasome inhibitor-induced cytotoxicity in malignant glioma.

Vlachostergios PJ, Voutsadakis IA, Papandreou CN.

Cell Biol Toxicol. 2013 Aug;29(4):199-211. doi: 10.1007/s10565-013-9248-z. Epub 2013 Jun 5. Review.

PMID:
23733249
28.

The role of ubiquitin-proteasome system in glioma survival and growth.

Vlachostergios PJ, Voutsadakis IA, Papandreou CN.

Growth Factors. 2013 Jun;31(3):106-13. doi: 10.3109/08977194.2013.799156. Epub 2013 May 21. Review.

PMID:
23688106
29.

Bortezomib overcomes MGMT-related resistance of glioblastoma cell lines to temozolomide in a schedule-dependent manner.

Vlachostergios PJ, Hatzidaki E, Befani CD, Liakos P, Papandreou CN.

Invest New Drugs. 2013 Oct;31(5):1169-81. doi: 10.1007/s10637-013-9968-1. Epub 2013 May 5.

PMID:
23645448
30.

MGMT repletion after treatment of glioblastoma cells with temozolomide and O6-benzylguanine implicates NFκB and mutant p53.

Vlachostergios PJ, Hatzidaki E, Papandreou CN.

Neurol Res. 2013 Oct;35(8):879-82. doi: 10.1179/1743132813Y.0000000191. Epub 2013 Mar 22.

PMID:
23561593
31.

The Bmi-1/NF-κB/VEGF story: another hint for proteasome involvement in glioma angiogenesis?

Vlachostergios PJ, Papandreou CN.

J Cell Commun Signal. 2013 Dec;7(4):235-7. doi: 10.1007/s12079-013-0198-2. Epub 2013 Mar 15.

32.

Bortezomib downregulates MGMT expression in T98G glioblastoma cells.

Vlachostergios PJ, Hatzidaki E, Stathakis NE, Koukoulis GK, Papandreou CN.

Cell Mol Neurobiol. 2013 Apr;33(3):313-8. doi: 10.1007/s10571-013-9910-2. Epub 2013 Jan 20.

PMID:
23334228
33.

Hashimoto's Thyroiditis and Kikuchi's Disease: Presentation of a Case and Review of the Literature.

Saratziotis A, Karakousis K, Tzika K, Oikonomou KG, Vlachostergios PJ.

Case Rep Otolaryngol. 2012;2012:267595. doi: 10.1155/2012/267595. Epub 2012 Nov 28.

34.

The ubiquitin-proteasome system in glioma cell cycle control.

Vlachostergios PJ, Voutsadakis IA, Papandreou CN.

Cell Div. 2012 Jul 20;7(1):18. doi: 10.1186/1747-1028-7-18.

35.

Neuropeptide-inducible upregulation of proteasome activity precedes nuclear factor kappa B activation in androgen-independent prostate cancer cells.

Patrikidou A, Vlachostergios PJ, Voutsadakis IA, Hatzidaki E, Valeri RM, Destouni C, Apostolou E, Papandreou CN.

Cancer Cell Int. 2012 Jun 20;12(1):31. doi: 10.1186/1475-2867-12-31.

36.

Expression of neutral endopeptidase, endothelin-1, and nuclear factor kappa B in prostate cancer: interrelations and associations with prostate-specific antigen recurrence after radical prostatectomy.

Vlachostergios PJ, Karasavvidou F, Kakkas G, Moutzouris G, Patrikidou A, Voutsadakis IA, Daliani DD, Zintzaras E, Melekos MD, Papandreou CN.

Prostate Cancer. 2012;2012:452795. doi: 10.1155/2012/452795. Epub 2012 May 15.

37.

The Glasgow Prognostic Score (GPS) predicts toxicity and efficacy in platinum-based treated patients with metastatic lung cancer.

Gioulbasanis I, Pallis A, Vlachostergios PJ, Xyrafas A, Giannousi Z, Perdikouri IE, Makridou M, Kakalou D, Georgoulias V.

Lung Cancer. 2012 Aug;77(2):383-8. doi: 10.1016/j.lungcan.2012.04.008. Epub 2012 Apr 30.

PMID:
22551892
38.

Selecting for predisposition to cancer cachexia.

Gioulbasanis I, Vlachostergios PJ, Papandreou CN.

EMBO Mol Med. 2012 Jun;4(6):451-2. doi: 10.1002/emmm.201200232. Epub 2012 Apr 11. No abstract available.

39.

Basic Concepts in Metastatic Cardiac Disease.

Vlachostergios PJ, Daliani DD, Papandreou CN.

Cardiol Res. 2012 Apr;3(2):47-48. doi: 10.4021/cr155w. Epub 2012 Mar 20. Review.

40.

Bortezomib reverses the proliferative and antiapoptotic effect of neuropeptides on prostate cancer cells.

Tsapakidis K, Vlachostergios PJ, Voutsadakis IA, Befani CD, Patrikidou A, Hatzidaki E, Daliani DD, Moutzouris G, Liakos P, Papandreou CN.

Int J Urol. 2012 Jun;19(6):565-74. doi: 10.1111/j.1442-2042.2012.02967.x. Epub 2012 Feb 10.

41.

CD10 is inversely associated with nuclear factor-kappa B and predicts biochemical recurrence after radical prostatectomy.

Voutsadakis IA, Vlachostergios PJ, Daliani DD, Karasavvidou F, Kakkas G, Moutzouris G, Melekos MD, Papandreou CN.

Urol Int. 2012;88(2):158-64. doi: 10.1159/000335299. Epub 2012 Jan 28.

PMID:
22286396
42.

Lack of prognostic significance of p16 and p27 after radical prostatectomy in hormone-naïve prostate cancer.

Vlachostergios PJ, Karasavvidou F, Kakkas G, Kapatou K, Gioulbasanis I, Daliani DD, Moutzouris G, Papandreou CN.

J Negat Results Biomed. 2012 Jan 5;11(1):2. doi: 10.1186/1477-5751-11-2.

43.

The Role of the Small Ubiquitin-Related Modifier (SUMO) Pathway in Prostate Cancer.

Vlachostergios PJ, Papandreou CN.

Biomolecules. 2012 Apr 23;2(2):240-55. doi: 10.3390/biom2020240.

44.

Neuroendocrine differentiation and the ubiquitin-proteasome system in cancer: Partners or enemies?

Vlachostergios PJ, Papandreou CN.

World J Exp Med. 2011 Dec 20;1(1):7-9. doi: 10.5493/wjem.v1.i1.7. eCollection 2011 Dec 20. Review.

45.

Baseline plasma levels of interleukin-8 in stage IV non-small-cell lung cancer patients: relationship with nutritional status and prognosis.

Gioulbasanis I, Patrikidou A, Kitikidou K, Papadimitriou K, Vlachostergios PJ, Tsatsanis C, Margioris AN, Papandreou CN, Mavroudis D, Georgoulias V.

Nutr Cancer. 2012;64(1):41-7. doi: 10.1080/01635581.2012.630157. Epub 2011 Nov 18.

PMID:
22098075
46.

Pulmonary and cutaneous nodules in an immunocompromised patient.

Vlachostergios PJ, Karamagkiolis S, Karamitsos K.

Thorax. 2011 Dec;66(12):1103, 1108. doi: 10.1136/thoraxjnl-2011-200757. Epub 2011 Oct 6. No abstract available.

PMID:
21979144
47.

Bortezomib represses HIF-1α protein expression and nuclear accumulation by inhibiting both PI3K/Akt/TOR and MAPK pathways in prostate cancer cells.

Befani CD, Vlachostergios PJ, Hatzidaki E, Patrikidou A, Bonanou S, Simos G, Papandreou CN, Liakos P.

J Mol Med (Berl). 2012 Jan;90(1):45-54. doi: 10.1007/s00109-011-0805-8. Epub 2011 Sep 10. Erratum in: J Mol Med (Berl). 2013 Jun;91(6):771-3.

PMID:
21909688
48.

Evidence of association between methylenetetrahydrofolate reductase gene and susceptibility to breast cancer: a candidate-gene association study in a South-eastern European population.

Papandreou CN, Doxani C, Zdoukopoulos N, Vlachostergios PJ, Hatzidaki E, Bakalos G, Ziogas DC, Koufakis T, Zintzaras E.

DNA Cell Biol. 2012 Feb;31(2):193-8. doi: 10.1089/dna.2011.1292. Epub 2011 Aug 29.

PMID:
21875371
49.

p53 and cyclooxygenase-2 expression are directly associated with cyclin D1 expression in radical prostatectomy specimens of patients with hormone-naïve prostate cancer.

Vlachostergios PJ, Karasavvidou F, Patrikidou A, Voutsadakis IA, Kakkas G, Moutzouris G, Zintzaras E, Daliani DD, Melekos MD, Papandreou CN.

Pathol Oncol Res. 2012 Apr;18(2):245-52. doi: 10.1007/s12253-011-9435-2. Epub 2011 Jul 23.

PMID:
21786090
50.

Mini Nutritional Assessment (MNA) and biochemical markers of cachexia in metastatic lung cancer patients: interrelations and associations with prognosis.

Gioulbasanis I, Georgoulias P, Vlachostergios PJ, Baracos V, Ghosh S, Giannousi Z, Papandreou CN, Mavroudis D, Georgoulias V.

Lung Cancer. 2011 Dec;74(3):516-20. doi: 10.1016/j.lungcan.2011.05.009. Epub 2011 May 31.

PMID:
21632145

Supplemental Content

Loading ...
Support Center